Julia A. Beaver

11.0k citations

134 papers · 5.3k · 3 hit papers · h-index 41

Impact in

Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
- Cancer-related Molecular Pathways
- CAR-T cell therapy research
Cancer Research top 2%
- Cancer Genomics and Diagnostics

Papers in

Oncology 54
- Cancer Immunotherapy and Biomarkers 26
- HER2/EGFR in Cancer Research 14
Pulmonary and Respiratory Medicine 45
- Advanced Breast Cancer Therapies 17
- Lung Cancer Treatments and Mutations 15

Co-authors: Richard Pazdur (90 shared papers)Shenghui Tang (44 shared papers)Marc R. Theoret (33 shared papers)Rajeshwari Sridhara (29 shared papers)Kirsten B. Goldberg (30 shared papers)Paul G. Kluetz (40 shared papers)Laleh Amiri‐Kordestani (36 shared papers)Harpreet Singh (39 shared papers)
Journals: Journal of Clinical Oncology (37 papers)Clinical Cancer Research (30 papers)The Oncologist (11 papers)JAMA Oncology (6 papers)New England Journal of Medicine (5 papers)
Partner nations: United States Canada Switzerland

In The Last Decade

Julia A. Beaver

125 papers receiving 5.2k citations

Julia A. Beaver's Hit Papers

align trajectories log scale

Trends in the approval of cancer therapies by the FDA in the twenty-first century 2023 · 172 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2023 Nature Reviews Drug Discovery
2021 Clinical Cancer Research
2021 Clinical Cancer Research

Peers

Countries citing papers authored by Julia A. Beaver

Since Specialization

Citations

This map shows the geographic impact of Julia A. Beaver's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julia A. Beaver with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julia A. Beaver more than expected).

Fields of papers citing papers by Julia A. Beaver

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julia A. Beaver. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julia A. Beaver. The network helps show where Julia A. Beaver may publish in the future.

Co-authors

The 25 scholars most cited alongside Julia A. Beaver, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Julia A. Beaver Line = papers co-authored together Julia A. Beaver links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 134 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden–High Solid Tumors Clinical Cancer Research ·Leigh Marcus, Lola A. Fashoyin‐Aje, Martha Donoghue, Mengdie Yuan, Lisa Rodríguez, Pamela Gallagher, Reena Philip, Soma Ghosh, Marc R. Theoret, Julia A. Beaver, Richard Pazdur, Steven J. Lemery Hit paper breakdown →	2021	358
2	FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer Clinical Cancer Research ·Julia A. Beaver, Laleh Amiri‐Kordestani, Rosane Charlab, Wei Chen, Todd R. Palmby, Amy Tilley, Jeanne Fourie Zirkelbach, Jingyu Yu, Qi Liu, Liang Zhao, Joyce Z. Crich, (unknown), Minerva Hughes, Erik Bloomquist, Shenghui Tang, Rajeshwari Sridhara, Paul G. Kluetz, Geoffrey Kim, Amna Ibrahim, Richard Pazdur, Patricia Cortazar	2015	279
3	Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody Journal of Clinical Oncology ·V. Ellen Maher, Laura L. Fernandes, Chana Weinstock, Shenghui Tang, Sundeep Agarwal, Michael H. Brave, Yang‐Min Ning, Harpreet Singh, Daniel L. Suzman, James Xu, Kirsten B. Goldberg, Rajeshwari Sridhara, Amna Ibrahim, Marc R. Theoret, Julia A. Beaver, Richard Pazdur	2019	235
4	A 25-Year Experience of US Food and Drug Administration Accelerated Approval of Malignant Hematology and Oncology Drugs and Biologics JAMA Oncology ·Julia A. Beaver, Lynn Howie, Lorraine Pelosof, Tamy Kim, Jinzhong Liu, Kirsten B. Goldberg, Rajeshwari Sridhara, Gideon M. Blumenthal, Ann T. Farrell, Patricia Keegan, Richard Pazdur, Paul G. Kluetz	2018	226
5	CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis The Lancet Oncology ·Jennifer Gao, Joyce Cheng, Erik Bloomquist, Jacquelyn Sanchez, Suparna Wedam, Harpreet Singh, Laleh Amiri‐Kordestani, Amna Ibrahim, Rajeshwari Sridhara, Kirsten B. Goldberg, Marc R. Theoret, Paul G. Kluetz, Gideon M. Blumenthal, Richard Pazdur, Julia A. Beaver, Tatiana M. Prowell	2019	204
6	FDA Approval Summary: Sotorasib for KRAS G12C -Mutated Metastatic NSCLC Clinical Cancer Research ·Erica C. Nakajima, Nicole Drezner, Xiaoxue Li, Pallavi S. Mishra‐Kalyani, Yajun Liu, Hong Zhao, Youwei Bi, Jiang Liu, Atiqur Rahman, Emily Wearne, Idara Ojofeitimi, Lauren Tesh Hotaki, Dianne Spillman, Richard Pazdur, Julia A. Beaver, Harpreet Singh Hit paper breakdown →	2021	202
7	Trends in the approval of cancer therapies by the FDA in the twenty-first century Nature Reviews Drug Discovery ·Emma Scott, Andrea Baines, Yutao Gong, Rodney Moore, Gülsüm Emel Pamuk, Haleh Saber, Ashim Subedee, Matthew D. Thompson, Wenming Xiao, Richard Pazdur, V. Ashutosh Rao, Julie A. Schneider, Julia A. Beaver Hit paper breakdown →	2023	172
8	FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy The Oncologist ·Daniel L. Suzman, Sundeep Agrawal, Yang‐Min Ning, V. Ellen Maher, Laura L. Fernandes, Stella Karuri, Shenghui Tang, Rajeshwari Sridhara, Jason Schroeder, Kirsten B. Goldberg, Amna Ibrahim, Amy E. McKee, Richard Pazdur, Julia A. Beaver	2018	141
9	FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma Clinical Cancer Research ·Elaine Chang, Chana Weinstock, Lijun Zhang, Rosane Charlab, Sarah E. Dorff, Yutao Gong, Vicky Hsu, Fang Li, Tiffany K. Ricks, Pengfei Song, Shenghui Tang, Peter Waldron, Jingyu Yu, Eias Zahalka, Kirsten B. Goldberg, Richard Pazdur, Marc R. Theoret, Amna Ibrahim, Julia A. Beaver	2020	136
10	FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer The Oncologist ·Shaily Arora, Sanjeeve Balasubramaniam, Hui Zhang, Tara Berman, Preeti Narayan, Daniel L. Suzman, Erik Bloomquist, Shenghui Tang, Yutao Gong, Rajeshwari Sridhara, Francisca Reyes Turcu, Deb Chatterjee, Banu Saritas-Yildirim, Soma Ghosh, Reena Philip, Anand Pathak, Jennifer Gao, Laleh Amiri‐Kordestani, Richard Pazdur, Julia A. Beaver	2020	131
11	FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer Clinical Cancer Research ·Preeti Narayan, Christy Osgood, Harpreet Singh, Haw-Jyh Chiu, Tiffany K. Ricks, Edwin C.Y. Chow, Junshan Qiu, Pengfei Song, Jingyu Yu, Frances Namuswe, Maria Guiterrez-Lugo, Sherry Hou, William F. Pierce, Kirsten B. Goldberg, Shenghui Tang, Laleh Amiri‐Kordestani, Marc R. Theoret, Richard Pazdur, Julia A. Beaver	2021	124
12	FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast Cancer Clinical Cancer Research ·Sakar Wahby, Lola A. Fashoyin‐Aje, Christy Osgood, Joyce Cheng, Mallorie H. Fiero, Lijun Zhang, Shenghui Tang, Salaheldin S. Hamed, Pengfei Song, Rosane Charlab, Sarah E. Dorff, Tiffany K. Ricks, Kimberly Barnett-Ringgold, Jeannette Dinin, Kirsten B. Goldberg, Marc R. Theoret, Richard Pazdur, Laleh Amiri‐Kordestani, Julia A. Beaver	2020	119
13	Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis The Lancet Oncology ·Julia A. Beaver, Maitreyee Hazarika, Flora Mulkey, Sirisha L. Mushti, Huanyu Chen, Kun He, Rajeshwari Sridhara, Kirsten B. Goldberg, Meredith K. Chuk, Dow-Chung Chi, Jennie Chang, Amy Barone, Sanjeeve Balasubramaniam, Gideon M. Blumenthal, Patricia Keegan, Richard Pazdur, Marc R. Theoret	2018	114
14	FDA Approval Summary: Palbociclib for Male Patients with Metastatic Breast Cancer Clinical Cancer Research ·Suparna Wedam, Lola A. Fashoyin‐Aje, Erik Bloomquist, Shenghui Tang, Rajeshwari Sridhara, Kirsten B. Goldberg, Marc R. Theoret, Laleh Amiri‐Kordestani, Richard Pazdur, Julia A. Beaver	2019	107
15	FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer The Oncologist ·Luckson Mathieu, Sujay Shah, Lee H. Pai-Scherf, Erin Larkins, Jonathon Vallejo, Xiaoxue Li, Lisa Rodríguez, Pallavi S. Mishra‐Kalyani, Kirsten B. Goldberg, Paul G. Kluetz, Marc R. Theoret, Julia A. Beaver, Richard Pazdur, Harpreet Singh	2021	104
16	The BOLERO-2 Trial: The Addition of Everolimus to Exemestane in the Treatment of Postmenopausal Hormone Receptor-Positive Advanced Breast Cancer Future Oncology ·Julia A. Beaver, Ben Ho Park	2012	94
17	FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor–Positive, HER2-Negative Advanced or Metastatic Breast Cancer Clinical Cancer Research ·Anand Shah, Erik Bloomquist, Shenghui Tang, Wentao Fu, Youwei Bi, Qi Liu, Jingyu Yu, Ping Zhao, Todd R. Palmby, Kirsten B. Goldberg, C.J. George Chang, Paresma Patel, Elleni Alebachew, Amy Tilley, William F. Pierce, Amna Ibrahim, Gideon M. Blumenthal, Rajeshwari Sridhara, Julia A. Beaver, Richard Pazdur	2018	90
18	Comparison of cell stabilizing blood collection tubes for circulating plasma tumor DNA Clinical Biochemistry ·Patricia Valda Toro, Bracha Erlanger, Julia A. Beaver, Rory L. Cochran, Dustin A. VanDenBerg, Elizabeth Yakim, Karen Cravero, David Chu, Daniel J. Zabransky, Hong Yuen Wong, Sarah Croessmann, Heather A. Parsons, Paula J. Hurley, Josh Lauring, Ben Ho Park	2015	83
19	External control arms in oncology: current use and future directions Annals of Oncology ·Pallavi S. Mishra‐Kalyani, L. Amiri Kordestani, Donna R. Rivera, Harpreet Singh, Amna Ibrahim, R. Angelo DeClaro, Yuan Li Shen, Shenghui Tang, R. Sridhara, Paul G. Kluetz, John Concato, Richard Pazdur, Julia A. Beaver	2022	83
20	U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early-Stage HER2-Positive Breast Cancer Clinical Cancer Research ·Harpreet Singh, Amanda J. Walker, Laleh Amiri‐Kordestani, Joyce Cheng, Shenghui Tang, Pamela Balcazar, Kimberly Barnett-Ringgold, Todd R. Palmby, Xianhua Cao, Nan Zheng, Qi Liu, Jingyu Yu, William F. Pierce, Selena Daniels, Rajeshwari Sridhara, Amna Ibrahim, Paul G. Kluetz, Gideon M. Blumenthal, Julia A. Beaver, Richard Pazdur	2018	78

About Julia A. Beaver

Julia A. Beaver is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Economics and Econometrics and Molecular Biology, having authored 134 papers that have together received 5.3k indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (30 papers), Cancer Immunotherapy and Biomarkers (26 papers), Health Systems, Economic Evaluations, Quality of Life (19 papers), Advanced Breast Cancer Therapies (17 papers), Lung Cancer Treatments and Mutations (15 papers), HER2/EGFR in Cancer Research (14 papers), Economic and Financial Impacts of Cancer (12 papers) and Biomedical Ethics and Regulation (11 papers). The work is most often cited by research in Oncology (2.5k citations), Cancer Research (879 citations), Pulmonary and Respiratory Medicine (1.5k citations), Statistics and Probability (199 citations) and Genetics (231 citations). Julia A. Beaver has collaborated with scholars based in United States, Canada and Switzerland. Frequent co-authors include Richard Pazdur, Shenghui Tang, Marc R. Theoret, Rajeshwari Sridhara, Kirsten B. Goldberg, Paul G. Kluetz, Laleh Amiri‐Kordestani, Harpreet Singh, Amna Ibrahim and Lola A. Fashoyin‐Aje. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, The Oncologist, JAMA Oncology and New England Journal of Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Julia A. Beaver

Impact in

Papers in i

In The Last Decade

Julia A. Beaver

Julia A. Beaver's Hit Papers

Peers

Countries citing papers authored by Julia A. Beaver

Fields of papers citing papers by Julia A. Beaver

All Works

About Julia A. Beaver

Explore authors with similar magnitude of impact

Papers in